PureTech Health plc
NASDAQ:PRTC · NASDAQ Global Market
+$0.45 today
Vol 0.00M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-35.2%
avg -3.5%
ROIC
-19.7%
avg -52.2%
ROA
-20.5%
avg -1.7%
Analysis
ROIC is currently the strongest return metric at -19.7% versus its period average of -52.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Lyne | CEO & Director | $732,776.00 | — | 43 | — | — |
Robert S. Langer Jr. | Co-Founder & Non-Executive Director | $270,000.00 | — | 77 | — | — |
Spencer Ball | Executive Vice President of Human Resources | — | — | — | — | — |
Allison Mead Talbot | Senior Vice President of Communications & Head of Investor Relations | — | — | — | — | — |
Aleksandra Filipovic | Head of Oncology | — | — | — | — | — |
Anita Terpstra | Senior Vice President of Intellectual Property | — | — | — | — | — |
Lauren A. White | Chief Financial Officer | — | — | 47 | — | — |
Eric Elenko | Co-Founder & President | — | — | 53 | — | — |
Charles Sherwood | General Counsel & Company Secretary | — | — | — | — | — |
Michael Inbar | Chief Accounting Officer | — | — | — | — | — |
David R. Elmaleh | Co-Founder & Senior Advisor | — | — | 78 | — | — |
Joy Bauer | Chief Nutrition Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -14.2% | +47.6% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -14.2% over three years. Forward estimates point to Revenue at +47.6% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Alumis Inc. Common Stock
NASDAQ:ALMS
$2.85B
Solid Biosciences Inc.
NASDAQ:SLDB
$590.17M
Neurogene Inc.
NASDAQ:NGNE
$496.34M
Autolus Therapeutics plc
NASDAQ:AUTL
$409.86M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$350.94M
Benitec Biopharma Inc.
NASDAQ:BNTC
$316.28M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$304.14M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$271.13M
Quantum-Si incorporated
NASDAQ:QSI
$193.17M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
Who manages PRTC?
PureTech Health plc (PRTC) lists 12 active executives. The top listed executive is Spencer Ball, Executive Vice President of Human Resources.
Explore More
Continue the stock analysis
Jump to another research area for this company.